Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma (ORIENT-15)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03748134
Recruitment Status : Recruiting
First Posted : November 20, 2018
Last Update Posted : September 22, 2020
Sponsor:
Information provided by (Responsible Party):
Innovent Biologics (Suzhou) Co. Ltd.

Brief Summary:
This is a randomized, double-blind multi-center, phase III study comparing the efficacy and safety of sintilimab or placebo in combination with chemotherapy as first-line treatment in subjects with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma.

Condition or disease Intervention/treatment Phase
Esophageal Squamous Cell Carcinoma Biological: Sintilimab Drug: Placebo Drug: Cisplatin Drug: Paclitaxel Drug: Fluorouracil Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 676 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination With Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)
Actual Study Start Date : December 13, 2018
Estimated Primary Completion Date : July 14, 2021
Estimated Study Completion Date : July 30, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Sintilimab + chemotherapy

Sintilimab in combination with investigator's choice of chemotherapy

TP regimen: Cisplatin + paclitaxel

or

CP regimen: Cisplatin + fluorourcil

Biological: Sintilimab
For weight <60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1

Drug: Cisplatin
75mg/m^2 IV Q3W day 1

Drug: Paclitaxel
87.5 mg/m^2 IV Q3W day 1, day 8 for first cycle and 175mg/m^2 IV Q3W day 1 after first cycle

Drug: Fluorouracil
800 mg/m^2 IV continuous infusion over 24 hours daily on Days 1-5 Q3W

Active Comparator: Placebo + chemotherapy

Placebo in combination with investigator's choice of chemotherapy

TP regimen: Cisplatin + paclitaxel

or

CP regimen: Cisplatin + fluorourcil

Drug: Placebo
For weight <60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1

Drug: Cisplatin
75mg/m^2 IV Q3W day 1

Drug: Paclitaxel
87.5 mg/m^2 IV Q3W day 1, day 8 for first cycle and 175mg/m^2 IV Q3W day 1 after first cycle

Drug: Fluorouracil
800 mg/m^2 IV continuous infusion over 24 hours daily on Days 1-5 Q3W




Primary Outcome Measures :
  1. OS in overall population [ Time Frame: From date of randomization until the date of death from any cause, assessed up to 40 months. ]
    To compare the overall survival of sintilimab vs. placebo, in combination with chemotherapy, for first-line treatment in subjects with unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)

  2. OS in PD-L1 positive population [ Time Frame: From date of randomization until the date of death from any cause, assessed up to 40 months. ]
    To compare the OS of sintilimab vs. placebo, in combination with chemotherapy, for first-line treatment in subjects with PD-L1 positive, unresectable, locally advanced, recurrent or metastatic ESCC


Secondary Outcome Measures :
  1. ORR in overall population [ Time Frame: From date of randomization up to 28 months. ]
    To compare the objective response rate between the two treatment arms in ITT population

  2. PFS in overall populationsubjects in ITT population [ Time Frame: From date of randomization up to 28 months ]
    To compare the progression-free survival between the two treatment arms in ITT population

  3. DCR in overall population [ Time Frame: From date of randomization up to 28 months ]
    To compare the disease control rate between the two treatment arms in ITT population

  4. DoR in overall population [ Time Frame: From date of randomization up to 28 months ]
    To compare the duration of response between the two treatment arms in ITT population

  5. ORR - PD-L1 positive [ Time Frame: From date of randomization up to 28 months ]
    To compare the objective response rate between the two treatment arms in PD-L1 positive subjects in ITT population

  6. DCR - PD-L1 positive [ Time Frame: From date of randomization up to 28 months ]
    To compare the disease control rate between the two treatment arms in PD-L1 positive subjects in ITT population

  7. DoR - PD-L1 positive [ Time Frame: From date of randomization up to 28 months ]
    To compare the duration of response between the two treatment arms in PD-L1 positive subjects in ITT population



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Histopathologically confirmed unresectable, locally advanced, recurrent or metastatic ESCC (excluding mixed adenosquamous carcinoma and other histological subtypes)
  • ECOG PS of 0 or 1
  • Subject must be unsuitable for definitive treatment, such as definitive chemoradiotherapy and/or surgery. For subjects who have received (neo)adjuvant or definitive chemotherapy/radiochemotherapy, time from the completion of last treatment to disease recurrence must be > 6 months Could provide archival or fresh tissues for PD-L1 expression analysis with obtainable results#
  • Have at least one measurable lesion as per RECIST v1.1

Key exclusion Criteria:

  • ESCC with endoscopy-confirmed near-complete obstruction requiring interventional therapy
  • Post stent implantation in the esophagus or trachea with risk of perforation
  • Received systemic treatment for advanced or metastatic ESCC.
  • Received a Cumulative dose of cisplatin > 300 mg/m2 within 12 months to randomization.
  • High risk of hemorrhage or perforations due to tumor invasion in adjacent organs (aorta or trachea), or have fistula formation.
  • Hepatic metastasis > 50% of the total liver volume.
  • Received palliative therapy for a local lesion within 2 weeks prior to the first dose.
  • Received systemic treatment with Chinese traditional medicines with anti-cancer indications or immunomodulators (including thymosins, interferons, and interleukins) within 2 weeks prior to the first dose of study treatment.
  • Received systemic immunosuppressants within 2 weeks prior to randomization, excluding local use of glucocorticoids administered by nasal, inhaled, or other routes, and systemic glucocorticoids at physiological doses (no more than 10 mg/day of prednisone or equivalents), or glucocorticoids to prevent allergies to contrast media.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03748134


Contacts
Layout table for location contacts
Contact: Agnes Sun +86 21 31820291 xiaolei.sun@innoventbio.com
Contact: Peter Pan +86 21 31655781 xinchun.pan@innoventbio.com

Locations
Layout table for location information
United States, California
St. Joseph Heritage Healthcare - Virginia K. Crosson Cancer Center Recruiting
Anaheim, California, United States, 92835
Contact    714-446-5900      
UC Irvine Recruiting
Orange, California, United States, 92868
Contact    949-824-5011      
United States, Colorado
Rocky Mountain Cancer Centers, LLP Recruiting
Denver, Colorado, United States, 80218
Contact    719-577-2555      
United States, Georgia
IACT Health - John B. Amos Cancer center Recruiting
Columbus, Georgia, United States, 31904
Contact    706-320-8700      
United States, Oklahoma
Oklahoma University Cancer Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact    405-271-1112      
United States, Texas
Texas Oncology, P.A. Recruiting
Austin, Texas, United States, 78705
Contact    512-427-9400      
United States, Washington
Northwest Cancer Specialists, P.C. Recruiting
Vancouver, Washington, United States, 98684
Contact    855-404-6727      
Australia, South Australia
The Queen Elizabeth Hospital Recruiting
Woodville South, South Australia, Australia, 5011
Contact    +65-8-8222 6000      
China
Beijing Cancer Hospital Recruiting
Beijing, China
Contact: Jiahui Liu         
Spain
University Hospital Marqués de Valdecilla Recruiting
Santander, Cantabria, Spain, 39008
Contact    +34 942 20 25 20      
Hospital Universitario La Paz Recruiting
Madrid, Spain, 28046
Contact    +34 917 27 70 00      
Sponsors and Collaborators
Innovent Biologics (Suzhou) Co. Ltd.
Layout table for additonal information
Responsible Party: Innovent Biologics (Suzhou) Co. Ltd.
ClinicalTrials.gov Identifier: NCT03748134    
Other Study ID Numbers: CIBI308A301
First Posted: November 20, 2018    Key Record Dates
Last Update Posted: September 22, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Innovent Biologics (Suzhou) Co. Ltd.:
ESCC
Esophageal Cancer
Esophageal Neoplasms
Esophageal Neoplasms Malignant
Esophageal Squamous Cell Carcinoma
Neoplasms, Squamous Cell
Esophageal Diseases
Carcinoma, Squamous Cell
Gastrointestinal Diseases
Paclitaxel
Cisplatin
Fluorouracil
Antineoplastic Agents
Anti-PD-1
Sintilimab
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Squamous Cell
Esophageal Squamous Cell Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Esophageal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Paclitaxel
Fluorouracil
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites
Antimetabolites, Antineoplastic
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs